Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1q.

R A Rudick, J M Bidlack, D W Knutson

    Archives of Neurology
    |September 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

    European journal of neurology·2020
    Same author

    Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2015
    Same author

    Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

    AJNR. American journal of neuroradiology·2014
    Same author

    Prescribing recommendations for interferon-Beta in multiple sclerosis.

    CNS drugs·2013
    Same author

    Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

    Neurology·2011
    Same author

    Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2011

    A C1q-binding assay detected soluble immune complexes in cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients, but results did not correlate with other disease markers, limiting its clinical use.

    Area of Science:

    • Neurology
    • Immunology
    • Clinical Chemistry

    Background:

    • Soluble immune complexes (sICs) in cerebrospinal fluid (CSF) are implicated in various neurological conditions.
    • Assessing sICs may offer insights into disease activity and diagnosis for neurological disorders like multiple sclerosis (MS).

    Purpose of the Study:

    • To evaluate the diagnostic utility of a C1q-binding assay for detecting soluble immune complexes in CSF.
    • To determine the correlation between CSF sICs and established markers of disease activity in multiple sclerosis.

    Main Methods:

    • A sensitive C1q-binding assay was employed to quantify sICs in 182 CSF samples.
    • CSF samples were obtained from patients with multiple sclerosis (MS), infectious/inflammatory diseases, noninflammatory neurologic disorders, and healthy controls.

    Related Experiment Videos

    Main Results:

    • Soluble immune complexes were detected in 16% of progressive MS, 38% of relapsing-remitting MS, and 55% of inflammatory disease patients.
    • No significant correlations were observed between C1q-binding assay results and CSF myelin basic protein, pleocytosis, oligoclonal bands, or IgG levels.
    • The assay showed low sensitivity and specificity, with 0% detection in controls.

    Conclusions:

    • The C1q-binding assay for CSF sICs demonstrates limited clinical usefulness for diagnosing or managing MS.
    • The lack of correlation with other CSF parameters suggests the assay is not a reliable indicator of disease activity in MS.